Patent US2238609A successfully refreshed from Google Patents.
Patent US780086A successfully refreshed from Google Patents.
US4067968A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Daunosamine nucleosides
Assignee: Pfizer Italia SRL
•
Filing: 1976-12-02
•
Granted: 1978-01-10
•
Expires: 1996-12-02
Abstract
Abstract The antitumor efficacy of the known antibiotics daunomycin (daunorubicin) and adriamycin (doxorubicin) is synergized by the use of said antibiotics together with a daunosamine nucleoside. The latter compounds are prepared by condensing a reactive protected daunosamine with a reactive protected heterocyclic base.
Inventors
- 👤 Ettore Lazzari
- 👤 Federico Arcamone
- 👤 Aurelio Di Marco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 15:37
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; A; A61; A61P; A61P35/00; C07H19/16
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
26 words
A daunosamine nucleoside of the formula: ##STR6##wherein R and R' are both H or R is COCF 3 and R' is COC 6 H 5 .
Claim 2
Dependent Claim
26 words
A daunosamine nucleoside of the formula: ##STR6##wherein R and R' are both H or R is COCF 3 and R' is COC 6 H 5 .
Claim 3
Dependent Claim
32 words
A daunosamine nucleoside of the formula: ##STR7##wherein R is H and R' is N(CH 3 ) 2 ; R is COCH 3 and R' is Cl or N(CH 3 ) 2 .
Claim 4
Dependent Claim
32 words
A daunosamine nucleoside of the formula: ##STR7##wherein R is H and R' is N(CH 3 ) 2 ; R is COCH 3 and R' is Cl or N(CH 3 ) 2 .
Claim 5
Dependent Claim
26 words
A daunosamine nucleoside of the formula: ##STR8##wherein R and R' are both H, or R is COCF 3 and R' is COC 6 H 5 .
Claim 6
Dependent Claim
26 words
A daunosamine nucleoside of the formula: ##STR8##wherein R and R' are both H, or R is COCF 3 and R' is COC 6 H 5 .
Claim 7
Dependent Claim
15 words
A daunosamine nucleoside of the formula: ##STR9## wherein R is H or COCF 3 .
Claim 8
Dependent Claim
15 words
A daunosamine nucleoside of the formula: ##STR9## wherein R is H or COCF 3 .
Claim 9
Dependent Claim
41 words
A composition comprising a therapeutically effective amount of the antitumor antibiotic daunomycin or adriamycin in combination with a synergizing amount of a daunosamine nucleoside selected from the group consisting of 9-(β-daunosaminyl)-adenine, 6-dimethyl-9-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-cytosine and 1-(β-daunosaminyl)-thymine and an inert carrier therefor.
Claim 10
Dependent Claim
41 words
A composition comprising a therapeutically effective amount of the antitumor antibiotic daunomycin or adriamycin in combination with a synergizing amount of a daunosamine nucleoside selected from the group consisting of 9-(β-daunosaminyl)-adenine, 6-dimethyl-9-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-cytosine and 1-(β-daunosaminyl)-thymine and an inert carrier therefor.
Claim 11
Dependent Claim
19 words
A composition according to claim 5, wherein the antibiotuc is adriamycin and the daunosamine nucleoside is 9-(β-daunosaminyl)-adenine or 1-(β-daunosaminyl)-cytosine.
Claim 12
Independent Claim
56 words
A method of inhibiting the growth of ascites sarcoma 180 which comprises intraperitoneally administering to a host afflicted with said tumor an amount of a compound selected from the group consisting of 9-(β-daunosaminyl)-adenine, 6-dimethyl-9-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-cytosine and 1-(β-daunosaminyl)-thymine sufficient to inhibit the growth of said tumor, in combination with a therapeutically effective amount of daunomycin or adriamycin.
Claim 13
Independent Claim
56 words
A method of inhibiting the growth of ascites sarcoma 180 which comprises intraperitoneally administering to a host afflicted with said tumor an amount of a compound selected from the group consisting of 9-(β-daunosaminyl)-adenine, 6-dimethyl-9-(β-daunosaminyl)-adenine, 1-(β-daunosaminyl)-cytosine and 1-(β-daunosaminyl)-thymine sufficient to inhibit the growth of said tumor, in combination with a therapeutically effective amount of daunomycin or adriamycin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-09 | 1981-07-11 | 1982-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-09 | 1985-07-11 | 1986-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-09 | 1989-07-11 | 1990-01-10 | $7700.00 | Window Closed / Lapsed |